Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

被引：0
|
作者：
Takahide Kimura
Seiki Yamada
Masayuki Tanemoto
机构：
[1] International University of Health and Welfare,Division of Nephrology, Department of Internal Medicine
来源：
SN Comprehensive Clinical Medicine | / 4卷 / 1期
关键词：
Chronic kidney disease; Gout; Hyperuricemia; Xanthine oxidase;
D O I：
10.1007/s42399-021-01081-1
中图分类号：
学科分类号：
摘要：
Hyperuricemia is a common complication of chronic kidney disease. Gout is a clinical symptom of hyperuricemia, and lowering serum uric acid concentration (sUA) is recommended to prevent its recurrence. Febuxostat and topiroxostat are sUA-lowering agents, which are presumed to act on the same site of xanthine oxidase (XO), the rate-limiting enzyme for urate production. We present a case of gout where febuxostat but not topiroxostat lowered sUA. The different efficacy between them indicates that XO inhibitors are not interchangeable even among those acting on the same site of XO.
引用
收藏
相关论文
共 50 条
  • [1] Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout
    Bruce, Susan P.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) : 2187 - 2194
  • [2] The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinolstudy protocol
    Sakuma, Masashi
    Toyoda, Shigeru
    Arikawa, Takuo
    Koyabu, Yota
    Kato, Toru
    Adachi, Taichi
    Suwa, Hideaki
    Narita, Jun-ichi
    Anraku, Koetsu
    Ishimura, Kimihiko
    Yamauchi, Fumitake
    Sato, Yasunori
    Inoue, Teruo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (06) : 1379 - 1386
  • [3] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Hiroshi Matsuo
    Eiji Ishikawa
    Hirofumi Machida
    Yasuhide Mizutani
    Akiko Tanoue
    Takahiro Ohnishi
    Tomohiro Murata
    Shinya Okamoto
    Toru Ogura
    Yuki Nishimura
    Hiroo Ito
    Masashi Yasutomi
    Kan Katayama
    Shinsuke Nomura
    Masaaki Ito
    Clinical and Experimental Nephrology, 2020, 24 : 307 - 313
  • [4] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Matsuo, Hiroshi
    Ishikawa, Eiji
    Machida, Hirofumi
    Mizutani, Yasuhide
    Tanoue, Akiko
    Ohnishi, Takahiro
    Murata, Tomohiro
    Okamoto, Shinya
    Ogura, Toru
    Nishimura, Yuki
    Ito, Hiroo
    Yasutomi, Masashi
    Katayama, Kan
    Nomura, Shinsuke
    Ito, Masaaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (04) : 307 - 313
  • [5] Hyperuricemia and xanthine oxidase in preeclampsia, revisited
    Many, A
    Hubel, CA
    Roberts, JM
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) : 288 - 291
  • [6] In Silico Prediction of Maize microRNA as a Xanthine Oxidase Inhibitor: A New Approach to Treating Hyperuricemia Patients
    Joshi, Manas
    Khan, Mohd Mabood
    NON-CODING RNA, 2025, 11 (01)
  • [7] Febuxostat: A Selective Xanthine-Oxidase/Xanthine-Dehydrogenase Inhibitor for the Management of Hyperuricemia in Adults With Gout
    Ernst, Michael E.
    Fravel, Michelle A.
    CLINICAL THERAPEUTICS, 2009, 31 (11) : 2503 - 2518
  • [8] Investigation of resveratrol as a xanthine oxidase inhibitor: Mechanistic insights and therapeutic implications for gout and hyperuricemia
    Chen, Jianmin
    Chen, Juan
    Feng, Baozhu
    Ning, Meilian
    Wu, Wanhui
    Zou, Shiqi
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2024,
  • [9] The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol—study protocol
    Masashi Sakuma
    Shigeru Toyoda
    Takuo Arikawa
    Yota Koyabu
    Toru Kato
    Taichi Adachi
    Hideaki Suwa
    Jun-ichi Narita
    Koetsu Anraku
    Kimihiko Ishimura
    Fumitake Yamauchi
    Yasunori Sato
    Teruo Inoue
    Clinical and Experimental Nephrology, 2018, 22 : 1379 - 1386
  • [10] Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
    Yu, Kuang-Hui
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 69 - 75
12345